BioElectronics Corp. (BIEL.PK), a maker of disposable drug-free anti-inflammatory devices, has been getting good press in recent times. The under-the-radar stock was first featured on RTTNews site on June 30 when it was trading at $0.0172. Since then, the stock has gained over 260% and now trades around $0.063.
The company's drug-free anti-inflammatory devices use wafer thin patches with embedded microchips and batteries that deliver pulsed electromagnetic energy. BioElectronics' products are marketed under the brand names ActiPatch, Allay and RecoveryRx. The products are approved for sale in over 20 countries including the U.S., Canada, Italy, India and Korea.
ActiPatch, the company's core product is approved in the U.S. by the FDA to reduce swelling following eyelid surgery (blepharoplasty). In Canada, it is approved for the relief of pain in musculoskeletal complaints.
The company has five kits marketed under ActiPatch brand -- for Back, Knee, Foot & Ankle, Wrist and Elbow. The sixth kit -- Allay Relief for menstrual pain is awaiting FDA clearance to be sold over the counter at retail stores.
According to the company, PEMF (portable electromagnetic field) therapy is a proven safe and effective alternative for many musculoskeletal disorders and there is a growing body of research showing its effectiveness in speeding surgical recovery and in reducing, or completely eliminating, the amount of pain medication required.
The painkillers like over the counter drug Tylenol, and prescription products Vicodin and Percocet contain the active ingredient Acetaminophen. There has been an increasing trend of abuse of painkillers in recent times. When taken more than the recommended dose Acetaminophen can cause liver damage and even death. Since BioElectronics offers drug-free solutions to pain relief, the company believes that its products are safe and effective alternative to Acetaminophen.
While providing an update on corporate activities on Friday, Andrew Whelan, CEO of BioElectronics said that the company has significantly reduced its level of convertible debt to less than $100,000 as of the end of June 2009 from approximately $910,000 as of the end of June 2008.
For the period ended March 31, 2009 the company has shrunk its loss to $36,468 from $416,369 by reining in the costs. Sales for the March quarter were $300 thousand, up from $120 thousand in the comparable quarter a year before. The company reveled that though its revenues are still relatively small, it is beginning to see growth, particularly within international markets. BioElectronics said that its gross margins exceed 70% even at relatively low revenue levels.
With a growing international distribution base, probable FDA clearances coming over the next few months and very strong margins, the company expects to be profitable over the coming quarters.
The company is not contemplating reverse stock splits or reverse mergers at this juncture.
A conference call is scheduled for Tuesday, July 28, during which, the company will provide an update on the results of a recently completed clinical study, status of current FDA filings and the additional FDA filings planned for the coming weeks.
Stay tuned...
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.